Cardiomyocyte Apoptosis Following Antegrade and Retrograde Cardioplegia

Cardiomyocyte Apoptosis Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01185912
• Other study ID #: 1/2006
• Status: Completed
• Phase: N/A
• First received: June 24, 2010
• Last updated: May 19, 2015
• Start date: January 2008
• Est. completion date: January 2010

Study information

• Verified date: May 2015
• Source: Turku University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Finland: Ethics Committee
• Study type: Observational

Clinical Trial Summary

Retrograde cardioplegia during heart surgery is associated with inadequate myocardial protection. In experimental animal study retrograde cardioplegia induces more cardiomyocyte apoptosis when compared to antegrade cardioplegia. 20 volunteer patients under going elective aortic valve surgery will be divided in to two groups: 10 patients receiving only antegrade cardioplegia and 10 patients receiving only retrograde cardioplegia. Pre- and post-operatively cardiac MRI and cardiac ultrasound will be performed. During the surgery ventricular muscle samples will be taken in order to assess cardiomyocyte apoptosis. Aims of the study: 1. whether the cardiomyocyte apoptosis is significantly more induced after retrograde cardioplegia than antegrade cardioplegia, 2. whether the amount of apoptotic cardiomyocytes correlates to conventional markers of myocardial injury after cardiac surgery, 3. whether the extent of irreversible myocardial damage by apoptosis correlates to post-ischemic contractile dysfunction after cardiac surgery, as measured with echocardiography, 4. whether the amount of cardiomyocyte apoptosis correlates to long term outcome and cardiac function as measured with MRI.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: January 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 60 Years to 90 Years

Eligibility

Inclusion Criteria:

• aortic valve stenosis or combined aortic valve disease

Exclusion Criteria:

• angiographically verified hemodynamically significant coronary artery disease impaired left ventricular function (left ventricular ejection fraction <50%) surgery including additional procedures other than aortic valve replacement cancer

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Cardiomyocyte Apoptosis

Intervention

Procedure:
• Ventricle muscle tissue samples

Locations

Country	Name	City	State
Finland	Turku University Hospital, Department of Surgery	Turku

Sponsors (2)

Lead Sponsor	Collaborator
Turku University Hospital	Finnish Foundation for Cardiovascular Research

Country where clinical trial is conducted

Finland,